Results from a controlled clinical trial from China on the use of hydroxychloroquine as a treatment for Covid-19 have shown no significant differences in health outcomes between the control group and patients who received the experimental drug.
The researchers who conducted the study, a team from the Shanghai Public Health Clinical Center in China, acknowledge that their clinical trial was small and a larger study would be necessary to confirm the results. The study also raises questions that remain unanswered about whether different dosages of hydroxychloroquine might bring different results.
Still, despite its limitations, the study results are important — helping us curb false hopes that may be encouraging us to abandon the more aggressive actions that we need to take to stop the spread of this disease. These results must also be considered in light of the real potential harmful side effects of hydroxychloroquine.